Natera
Natera is recorded as a service provider in 26 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 26 trials · Latest update first
A Phase 2 Study of Cemiplimab (Anti-PD-1 Antibody) in Combination with BNT116 (FixVac Lung) versus Cemiplimab Monotherapy in First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with Tumors Expressing PD-L1 ≥50%
Sponsor Regeneron Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Participants with Stage 4 Non-Small Cell Lung Cancer (TeLuRide-008).
Sponsor Eikon Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
PRODIGE 88 (FFCD 2002) CIRCULATE MRD PAC: A phase III multicentric, open-label, randomized study of chemotherapy in patients with positive ctDNA after surgery and adjuvant chemotherapy for high-risk stage II and stage III colorectal cancer
Sponsor Centre Hospitalier Universitaire De Dijon
- Start (EU)
- Latest update
- Estimated end
- Not reported
An Open-label, Single-Arm, Phase 2 Study to Evaluate Enfortumab Vedotin plus Pembrolizumab for Bladder Preservation in Participants with Muscle-invasive Bladder Cancer (EV-209).
Sponsor Astellas Pharma Global Development Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Phase 2 Study of Pembrolizumab And Chemotherapy With or Without MK-4830 as Neoadjuvant Treatment for High-Grade Serous Ovarian Cancer
Sponsor Merck Sharp & Dohme LLC
- Start (EU)
- Latest update
- Estimated end
A Phase 2 Peri-operative Trial of Fianlimab and Cemiplimab Compared with Anti-PD1 Alone in Patients with Resectable Stage III and IV Melanoma
Sponsor Regeneron Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomized Phase 3 Double-Blinded Study Comparing the Efficacy and Safety of Niraparib to Placebo in Participants With Either HER2-Negative BRCA-Mutated or Triple-Negative Breast Cancer With Molecular Disease Based on Presence of Circulating Tumor DNA After Definitive Therapy (ZEST)
Sponsor Glaxosmithkline Research & Development Limited
- Start (EU)
- Latest update
- Estimated end
A proof of concept study to evaluate treatments´efficacy by monitoring Minimal Residual Disease using ctDNA in HR-positive/HER2-negative early breast cancer population. -The MIRADOR study-
Sponsor Medica Scientia Innovation Research S.L.
- Start (EU)
- Latest update
- Estimated end
A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTIPD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB-IIIA NONSMALL CELL LUNG CANCER
Sponsor F. Hoffmann-La Roche AG
- Start (EU)
- Latest update
- Estimated end
PRODIGE 70 - CIRCULATE - CIRCULATING TUMOR DNA BASED DECISION FOR ADJUVANT TREATMENT IN COLON CANCER STAGE II
Sponsor Centre Hospitalier Universitaire De Dijon
- Start (EU)
- Latest update
- Estimated end
- Not reported
Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination with Pembrolizumab Versus Investigator’s Choice in HLA-A*02:01-positive Participants with Previously Treated Advanced Melanoma (TEBE-AM)
Sponsor Immunocore Limited
- Start (EU)
- Latest update
- Estimated end
A Phase III, Multicenter, Randomized, Open-Label Study of Atezolizumab (Anti-PD-L1 Antibody) Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients with Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation
Sponsor F. Hoffmann-La Roche AG
- Start (EU)
- Latest update
- Estimated end
A Phase I/IIa, open-label, dose finding, safety, tolerability and exploratory trial of THEO-260 in patients with high grade serous or endometrioid ovarian cancer
Sponsor Theolytics Limited
- Start (EU)
- Latest update
- Estimated end
A Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2/3 Study to Evaluate the Safety and Efficacy of EIK1001 and Pembrolizumab Versus Placebo and Pembrolizumab as First-Line Therapy in Participants with Advanced Melanoma (TeLuRide-006)
Sponsor Eikon Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A first-in-human, Phase 1/2, open-label, multi-center, dose-escalation, dose-optimization, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of PARP1-selective inhibitor, EIK1003 (IMP1734), as monotherapy and in combination in participants with advanced solid tumors.
Sponsor Eikon Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
EORTC 2129-BCG: Elacestrant for treating ER+/HER2- breast cancer patients with ctDNA relapse (TREAT ctDNA)
Sponsor European Organisation For Research And Treatment Of Cancer
- Start (EU)
- Latest update
- Estimated end
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab with or without Tiragolumab (Anti-Tigit Antibody) in Patients with Unresectable Esophageal Squamous Cell Carcinoma whose Cancers have not Progressed following Definitive Concurrent Chemoradiotherapy
Sponsor F. Hoffmann-La Roche AG
- Start (EU)
- Latest update
- Estimated end
A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH ADVANCED LIVER CANCERS (MORPHEUS LIVER)
Sponsor F. Hoffmann-La Roche AG
- Start (EU)
- Latest update
- Estimated end
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients with Urothelial Carcinoma (MORPHEUS-UC)
Sponsor F. Hoffmann-La Roche AG
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Randomized, Open-Label Study Comparing Telisotuzumab Adizutecan (ABBV-400) Monotherapy to the Current Standard of Care in Subjects with Post Adjuvant ctDNA Positive Colorectal Cancer and No Radiographic Evidence of Disease (NED)
Sponsor AbbVie Deutschland GmbH & Co. KG
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Natera?
The 2026-10-09 snapshot links Natera to 26 distinct CTIS trials. Recorded services include Laboratory services, ctDNA analysis and Whole Exome sequencing, Manufacturer of one of the IVDs used for liquid biopsy, Primary or surrogate end point examinations and ct DNA on blood sample - liquid biopsy, among 9 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Natera?
The most frequently recorded therapeutic areas are Solid Tumor Oncology, Dermatology, Gastroenterology, Gynecology. Recorded phases include Phase 2, Phase 3, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Natera conducted?
The linked trials record locations in 21 countries, including Spain, France, Italy, Germany, Poland. These are trial locations, not confirmed office locations or countries where Natera delivered services.
What can this page tell me about Natera's trial experience?
Browse 26 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Natera. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Natera Inc.